FOLH1 and Familial prostate cancer: The A10 aptamer specifically targeted prostate cancer cells expressing the cell-surface receptor PSMA (prostate-specific membrane antigen), allowing the delivery of therapeutic CRISPR/Cas9-gRNA targeting the survival gene polo-like kinase 1.